Study confirms the sensitivity of Techcyte’s AI solution for intestinal protozoa detection

A study authored by researchers at Quest Diagnostics and presented at ASM Microbe on June 9-12th 2022 in Washington, D.C. provides evidence that the Techcyte technology aids in the detection of intestinal protozoa. To perform the study, researchers chose software created by Techcyte, the clinical pathology AI platform. For years the gold standard for intestinal [...]

Study confirms the sensitivity of Techcyte’s AI solution for intestinal protozoa detection2022-06-30T11:54:03-06:00

AI-Powered Mold and Air Quality Testing Now Available to Home Inspectors and Laboratories

Techcyte, the leader in AI-powered clinical pathology diagnostics, is proud to announce Sporecyte, the first AI-powered mold and air quality reporting service, with next-day and same-day turnaround, available to home inspectors and Indoor Air Quality laboratories (IAQ). The World Health Organization reports that over 50% of homes have mold problems, while the National Association of [...]

AI-Powered Mold and Air Quality Testing Now Available to Home Inspectors and Laboratories2022-05-31T10:59:49-06:00

Techcyte and Cytobay Partner to Create Non-Invasive Digital Diagnostic Test for Bladder Cancer

Bladder cancer is one of the most common cancers and has a high recurrence rate.  After successful treatment, it is recommended that survivors be tested every three to six months for the first two years, every six to twelve months for years three to four, and then yearly from then on. This invasive test for [...]

Techcyte and Cytobay Partner to Create Non-Invasive Digital Diagnostic Test for Bladder Cancer2022-05-31T10:56:30-06:00

Techcyte and Cytobay Partner to Create Non-Invasive Digital Diagnostic Test for Bladder Cancer

Bladder cancer is one of the most common cancers and has a high recurrence rate.  After successful treatment, it is recommended that survivors be tested every three to six months for the first two years, every six to twelve months for years three to four, and then yearly from then on. This invasive test for [...]

Techcyte and Cytobay Partner to Create Non-Invasive Digital Diagnostic Test for Bladder Cancer2022-05-27T10:33:50-06:00

Zoetis adds Techcyte-powered AI Blood Smear Testing to Vetscan Imagyst

As the technology engine behind the multi-use AI-driven platform, Vetscan Imagyst, Techcyte is proud to announce the addition of artificial intelligence (AI) blood smear diagnostics testing. Vetscan Imagyst is Zoetis’s deep learning SaaS platform that uses image analysis to assist veterinary clinics with an accurate and efficient blood differential. Techcyte has collaborated with Zoetis—the world’s [...]

Zoetis adds Techcyte-powered AI Blood Smear Testing to Vetscan Imagyst2022-04-19T18:57:05-06:00

Techcyte earns ISO 13485 compliance

Techcyte has earned ISO 13485:2016 compliance for its quality management system.  When it comes to medical device manufacturing, patient safety greatly depends on the quality and consistency of medical products, and ensuring effectiveness, control and maintenance of quality management systems is critical to customers, patients, users, and regulatory agencies.  The process-based quality management system standard [...]

Techcyte earns ISO 13485 compliance2022-04-19T10:09:27-06:00

Hamamatsu partners with Techcyte to improve whole slide imaging

Digital pathology has long been synonymous with the digitization of histology (tissue-based) samples. Liquid-based samples, however, are notoriously difficult to scan, as the objects of interest are suspended at different focal depths and can be sparse, which makes focusing a challenging task for scanners. Hamamatsu has just announced their partnership with Techcyte where we are [...]

Hamamatsu partners with Techcyte to improve whole slide imaging2021-12-15T04:41:43-06:00

Techcyte’s 5 Phases of Innovation in AI

In the most recent episode of the “Digital Pathology Place” podcast, Ben Cahoon, our CEO, talks about the path to innovation that guides their development. Currently, Techcyte algorithms are phase one developments: they count and classify target objects, and present them to skilled operators. In this first phase, automation and accuracy are the goals. An [...]

Techcyte’s 5 Phases of Innovation in AI2021-11-10T09:49:01-06:00

Techcyte Closes $21 Million Funding Round

On August 18th 2021 in Orem, Utah, Techcyte Inc. closed a $21 million funding round to accelerate the commercialization of its digital clinical pathology platform. The investors in this round include Zoetis, ARUP Laboratories and investors from previous rounds. Ben Cahoon, the CEO of Techcyte, said, “Our relationship with Zoetis has been incredible as we’ve [...]

Techcyte Closes $21 Million Funding Round2021-08-19T06:20:40-06:00

University of Utah, ARUP, and Techcyte Develop NanoSpot.AI, a New Ultra-Fast Test for COVID-19 Antibodies

University of Utah, ARUP, and Techcyte Develop NanoSpot.AI, a New Ultra-Fast Test for COVID-19 Antibodies SALT LAKE CITY–The University of Utah (the U), ARUP Laboratories, and Techcyte Inc. announced today that they have formed a partnership to develop NanoSpot.AI, a less than five-minute, easy-to-administer SARS-CoV-2 antibody test. NanoSpot.AI is estimated to be significantly less [...]

University of Utah, ARUP, and Techcyte Develop NanoSpot.AI, a New Ultra-Fast Test for COVID-19 Antibodies2021-08-18T09:42:00-06:00
Go to Top